Flavio Solca
Impact in
- Oncology top 1%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
-
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 50
- HER2/EGFR in Cancer Research 28
- Lung Cancer Research Studies 8
- Colorectal Cancer Treatments and Studies 6
- Cancer-related Molecular Pathways 6
-
- Lung Cancer Treatments and Mutations 44
- Co-authors
- Frank Himmelsbach (5 shared papers)Anke Baum (10 shared papers)Heidi Greulich (3 shared papers)Takeshi Shimamura (2 shared papers)Lucian R. Chirieac (1 shared paper)Shigeto Kubo (1 shared paper)Lauren Ambrogio (1 shared paper)Robert F. Padera (1 shared paper)
- Journals
- Annals of Oncology (9 papers)Cancer Research (8 papers)European Journal of Cancer (5 papers)Journal of Clinical Oncology (5 papers)Molecular Cancer Therapeutics (4 papers)
- Partner nations
- AustriaGermanyUnited States
In The Last Decade
Flavio Solca
87 papers receiving 3.9k citations
Flavio Solca's Hit Papers
Peers
Comparison fields: 5 of 103
- Oncology 1.9k
- Pulmonary and Respiratory Medicine 1.7k
- Molecular Biology 1.7k
- Cancer Research 335
- Otorhinolaryngology 74
Countries citing papers authored by Flavio Solca
This map shows the geographic impact of Flavio Solca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavio Solca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavio Solca more than expected).
Fields of papers citing papers by Flavio Solca
This network shows the impact of papers produced by Flavio Solca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavio Solca. The network helps show where Flavio Solca may publish in the future.
Co-authors
The 25 scholars most cited alongside Flavio Solca, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Hit paper breakdown → | 2008 | 1202 |
| 2 | Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker Hit paper breakdown → | 2012 | 713 |
| 3 | Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. | 1989 | 204 |
| 4 | 2012 | 175 | |
| 5 | 2012 | 137 | |
| 6 | 2020 | 103 | |
| 7 | 2014 | 89 | |
| 8 | 2013 | 81 | |
| 9 | 2018 | 70 | |
| 10 | 2011 | 64 | |
| 11 | 2007 | 60 | |
| 12 | 1993 | 57 | |
| 13 | 1989 | 57 | |
| 14 | 1996 | 51 | |
| 15 | 2010 | 48 | |
| 16 | 2020 | 45 | |
| 17 | 2004 | 41 | |
| 18 | 2015 | 40 | |
| 19 | 2017 | 39 | |
| 20 | 1991 | 38 |
About Flavio Solca
Flavio Solca is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cell Biology and Radiology, Nuclear Medicine and Imaging, having authored 88 papers that have together received 4.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (44 papers), HER2/EGFR in Cancer Research (28 papers), PI3K/AKT/mTOR signaling in cancer (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Lung Cancer Research Studies (8 papers), Receptor Mechanisms and Signaling (6 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer-related Molecular Pathways (6 papers). The work is most often cited by research in Oncology (1.9k citations), Pulmonary and Respiratory Medicine (1.7k citations), Molecular Biology (1.7k citations), Cancer Research (335 citations) and Otorhinolaryngology (74 citations). Flavio Solca has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Frank Himmelsbach, Anke Baum, Heidi Greulich, Takeshi Shimamura, Lucian R. Chirieac, Shigeto Kubo, Lauren Ambrogio, Robert F. Padera, Masaya Takahashi and Matthew Meyerson. Their work appears in journals such as Annals of Oncology, Cancer Research, European Journal of Cancer, Journal of Clinical Oncology and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.